ANCA ASSOCIATED VASCULITIS (AAV)
Clinical trials for ANCA ASSOCIATED VASCULITIS (AAV) explained in plain language.
Never miss a new study
Get alerted when new ANCA ASSOCIATED VASCULITIS (AAV) trials appear
Sign up with your email to follow new studies for ANCA ASSOCIATED VASCULITIS (AAV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a single cell therapy tame four childhood autoimmune diseases?
Disease control Recruiting nowThis study tests a new treatment called Descartes-08 in 50 children, teens, and young adults with four autoimmune diseases: lupus, vasculitis, myasthenia gravis, and dermatomyositis. The treatment uses the patient's own modified cells to calm the immune system. The main goal is t…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: PHASE1, PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
New hope for rare blood vessel disease: phase 3 trial of BDB-001 underway
Disease control Recruiting nowThis study tests whether adding BDB-001 injection to standard treatments (cyclophosphamide/azathioprine or rituximab) helps more people with ANCA-associated vasculitis reach remission. About 300 adults with active GPA or MPA will participate. The goal is to reduce disease activit…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: PHASE3 • Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
New mRNA therapy tested for lupus and other autoimmune conditions
Disease control Recruiting nowThis early-stage trial tests a new mRNA drug called MTS109 in 15 people with moderate to severe autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. The main goal is to see if the treatment is safe and tolerable. Researchers will also check if it helps control the…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 17, 2026 02:01 UTC
-
Engineered immune cells take aim at lupus and MS
Disease control Recruiting nowThis early-stage study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and calm overactive immune cells in autoimmune diseases. The trial includes 18 adults with conditions like lupus, systemic sclerosis, multiple sclerosis, and ot…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Universal CAR T-Cells aim to tame autoimmune attacks in early trial
Disease control Recruiting nowThis study tests a new treatment using specially engineered immune cells (CAR T-cells) that target two proteins, CD19 and BCMA, found on faulty immune cells. The goal is to see if it is safe and can help control severe autoimmune diseases like lupus and scleroderma that have not …
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThis early-stage study is testing a new treatment called QT-019C, which uses specially engineered immune cells (CAR T-cells) to target and attack faulty cells that drive autoimmune diseases like lupus and scleroderma. The therapy is given as a one-time infusion and aims to reset …
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Immune cell therapy shows promise for tough autoimmune cases
Disease control Recruiting nowThis study tests a new treatment using specially engineered immune cells (CAR-NK) for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't responded to standard therapies. The treatment aims to control the overactive immune system and reduce…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
Could CAR-T therapy tame severe vasculitis? new trial launches
Disease control Recruiting nowThis study tests a new treatment called rapcabtagene autoleucel (a CAR-T cell therapy) against standard care for people with severe active vasculitis (GPA or MPA). About 126 adults aged 18-75 with confirmed ANCA antibodies and active disease will take part. The goal is to see if …
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
Blood test could end guesswork in treating arthritis and autoimmune diseases
Diagnosis Recruiting nowThis study is testing a new blood test that may help doctors choose the most effective drug for each person with rheumatic diseases like rheumatoid arthritis or lupus. The test looks at how a person's immune cells react to different medications before treatment starts. The goal i…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Sponsor: University of Bonn • Aim: Diagnosis
Last updated May 06, 2026 16:15 UTC
-
Full-Body PET scans may unmask hidden vasculitis and heart danger
Knowledge-focused Recruiting nowThis study uses advanced total-body PET scans with three different tracers to see if they can accurately measure disease activity in people with ANCA vasculitis, a serious autoimmune condition. Researchers will compare scan results with standard tests and also check heart disease…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Sponsor: University of Edinburgh • Aim: Knowledge-focused
Last updated May 17, 2026 02:06 UTC